Tapentadol Versus Oxycodon - a Mechanism-based Treatment Approach in Neuropathic Pain
Information source: University of Schleswig-Holstein
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Peripheral Neuropathy
Intervention: tapentadol, oxycodone (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University of Schleswig-Holstein Official(s) and/or principal investigator(s):
Ralf Baron, Prof. Dr., Principal Investigator, Affiliation: Head of Unit of Neuropathic Pain Research and Therapy, Department of Neurology, University Clinic Kiel
Overall contact:
Ralf Baron, Prof Dr, Phone: 00494315978505, Email: r.baron@neurologie.uni-kiel.de
Summary
The purpose of this study is to elucidate whether the additional mechanism of analgesia,
i. e. reuptake inhibition of norepinephrine, of tapentadol leads to a change in different
pain signs and symptoms in comparison to oxycodone.
Clinical Details
Official title: Phase 4 Study of Tapentadol vs Oxycodone in Neuropathic Pain
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Primary outcome: QST parameters on mechanical and thermal thresholds (detailed below)mechanical pain threshold (MPT) mechanical pain sensitivity (MPS) dynamic mechanicl allodynia (DMA) wind-up ratio (WUR)
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- thermal or mechanical hyperalgesia
- chronic neuropathic pain (NRS => 6)
Exclusion Criteria:
- non-specific
Locations and Contacts
Ralf Baron, Prof Dr, Phone: 00494315978505, Email: r.baron@neurologie.uni-kiel.de
Division for Neurological Pain Research and Therapy, Kiel, Schleswig Holstein 24105, Germany; Recruiting
Andreas Binder, Dr, Sub-Investigator
Additional Information
Starting date: October 2011
Last updated: June 6, 2012
|
